Since the antibody panel was nonreactive with the pooled plasma and the dilution control was valid, the MLS knew that the patient likely produced either an anti-Ch or anti-Rg and was able to rule out common clinically significant red cell antibodies. Since antisera was not available to type the patient, the MLS called the antibody an "HTLA-Like" antibody with a probable Chido or Rodgers specificity and recommended ABO/Rh compatible blood, and requested an urgent release of least incompatible blood authorization form from the attending physician.
